Mara Elisabeth, Mader Tobias, Gratzer Johannes, Hochegger Stefanie, Pekar Thomas
Biomedical Science, University of Applied Sciences Wiener Neustadt, Austria.
Clin Immunol Commun. 2022 Dec;2:136-141. doi: 10.1016/j.clicom.2022.08.001. Epub 2022 Sep 14.
Since December 2019 the world has been dealing with a severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) pandemic. The first SARS-CoV-2 vaccine was made available in Europe at the end of 2020. 202 volunteers from the vicinity of the University of Applied Sciences Wiener Neustadt took part in this study; their IgG levels recognizing the RBD of SARS-CoV-2 were determined. The aim was to evaluate the SARS-CoV-2 titer levels of vaccinated, recovered and vaccinated plus recovered persons. We could show that there is a significant difference in the antibody levels of vaccinated, vaccinated plus recovered and only recovered probands. Additionally, the highest antibody levels were found in triple vaccinated persons. Furthermore, the Moderna vaccine seems to have a higher immune response.
自2019年12月以来，全球一直在应对严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）大流行。2020年底，首款SARS-CoV-2疫苗在欧洲上市。来自维也纳新城应用科学大学附近地区的202名志愿者参与了这项研究；测定了他们识别SARS-CoV-2受体结合域（RBD）的IgG水平。目的是评估接种疫苗者、康复者以及接种疫苗加康复者的SARS-CoV-2滴度水平。我们能够证明，接种疫苗者、接种疫苗加康复者以及仅康复的受试者的抗体水平存在显著差异。此外，在接种三针疫苗的人群中发现了最高的抗体水平。此外，Moderna疫苗似乎具有更高的免疫反应。
